苏伦嘎

Cooley advised EpimAb Biotherapeutics, a clinical-stage biotech company specializing in bispecific antibody development, on its $120 million Series C financing. China Merchants Bank International and Mirae Asset Financial Group co-led the round, which also included participation by Hony Capital, Cormorant Asset Management and other new investors, as well as existing investors such as Decheng Capital, SDIC Fund and Sherpa Healthcare Partners. EpimAb will use the new capital for the ongoing clinical development of three of its clinical assets and to expand its pipeline of novel bispecific antibodies and other biologics. Partner James Lu led the team advising EpimAb on the financing round.

Cooley advised InxMed on its $50 million Series B financing. Partner Christina Zhang led the team advising InxMed, which is a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors.

CS Capital led the round, with participation from AIHC Fund, Growth Fund and Hosencare Fund, as well as existing investor Ennovation Ventures. InxMed will use the funds to accelerate ongoing clinical trials of IN10018 for multiple cancer types in the US and China, to advance more stroma-targeting pipelines into clinics this year, and to strengthen research and development capabilities in Nanjing, China.

Cooley advised Chimagen Biosciences, a privately held biotechnology company, on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK, a global biopharma company, for an upfront payment of $300 million, plus success-based development and commercial milestone payments totaling up to $550 million.

Cooley advised D3 Bio – an emerging global biotechnology company that focuses on discovery, development and registration of innovative cancer drugs – on the close of its $62 million Series A+ financing.

Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.